Diazyme offers Lipoprotein(a) cobas c specific packaging for clinical chemistry analyzers

May 2, 2013

Diazyme Laboratories is now offering cobas c specific packaging for its FDA 510(k) cleared Lipoprotein(a) reagent assay. Diazyme's Lp(a) latex-enhanced immunoturbidimetric assay can be utilized to measure total levels of Lp(a) concentration in human serum or plasma samples as part of a work-up of patients with lipid metabolism disorders. Lp(a) is a cholesterol-rich lipoprotein particle found in human serum that assists in the assessment of atherosclerotic cardiovascular diseases in specific populations.

According to Diazyme spokespersons, the Lp(a) cobas c specific packaging is designed to work on most Roche clinical chemistry analyzers and provides a convenient, efficient, and cost-effective method for laboratories of virtually all sizes. The cobas c-pack packaging eliminates the need for reagent transfer, thereby reducing potential spillover and contamination. The Diazyme Lp(a) assay joins other products provided by the company including diagnostic blood tests for cardiac markers, diabetes, nutritional assessment, liver disease, renal disease and electrolytes. Read more about the Diazyme Lp(a).